# A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10

> **NCT07304258** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Hebei Medical University** · enrollment: 30 (estimated)

## Conditions studied

- Gastric Cancer Peritoneal Metastases

## Interventions

- **DEVICE:** HIPEC
- **DEVICE:** NIPS
- **DRUG:** Paclitaxel Injection, S-1, tislelizumab

## Key facts

- **NCT ID:** NCT07304258
- **Lead sponsor:** Hebei Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-12
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07304258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07304258, "A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07304258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*